Psychedelic compounds as a new approach to treating autoimmune conditions

Proposes that psychedelics including DMT and ayahuasca alkaloids may treat autoimmune conditions through potent anti-inflammatory effects mediated by 5-HT2A receptor activation. Reviews evidence that serotonergic psychedelics suppress TNF-alpha, IL-1beta, and other inflammatory cytokines. Suggests a novel therapeutic application.